Stephen Feider - 29 Jan 2025 Form 4 Insider Report for Beta Bionics, Inc. (BBNX)

Reporting relationship: Chief Financial Officer
Issuer ticker: BBNX
Reported as of: 29 Jan 2025
Net transaction value: $0
SEC form: 4
Accepted by SEC: 31 Jan 2025, 16:30:36 UTC
Next SEC filing: 03 Feb 2025
Source filing: View source filing
Reporting owner signature: /s/ Stephen Feider

Key filing fact

Stephen Feider filed Form 4 for Beta Bionics, Inc. (BBNX) on 31 Jan 2025.

Key facts

This page summarizes Stephen Feider's Form 4 filing for Beta Bionics, Inc. (BBNX).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 31 Jan 2025, 16:30.

Change

No earlier filing in this sequence is available for direct comparison.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

BBNX transaction Derivative

Employee Stock Option (right to buy)

Award

Transaction value: $0
Shares: +186,203
Change %
Price: $0.000000
Shares after: 186,203
Date: 29 Jan 2025
Ownership: Direct
Underlying class: Class B Common Stock
Underlying amount: 186,203
Exercise price: $17.00
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

Vesting is monthly over a 48-month period starting January 29, 2025 in equal monthly amounts.

Footnote F2

Immediately prior to the closing of the initial public offering, each share of Class B Common Stock subject to this option was converted into an equal number of shares of Common Stock.